Class / Patent application number | Description | Number of patent applications / Date published |
514200000 | 1-thia-5-aza-bicyclo (4.2.0) octane ring containing (including dehydrogenated) (e.g., cephalosporins, etc.) | 75 |
20100160278 | STABILIZED FREEZE-DRIED FORMULATION FOR CEPHALOSPORIN DERIVATIVES - The present invention relates to a freeze-dried formulation for cephalosporin derivatives having increased stability, a solution for obtaining and a method for preparing such a formulation, as well as the use of certain compounds for stabilizing cephalosporin derivatives in freeze-dried formulations. The compounds preferably used as stabilizers according to the invention are mannitol, trehalose, and PVP. | 06-24-2010 |
20140315876 | BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 10-23-2014 |
514201000 | 7,7-di-substituted | 1 |
20130079318 | BETA-LACTAMASE INHIBITORY COMPOUNDS - Inhibitors of the enzyme beta-lactamase are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided. | 03-28-2013 |
514202000 | Additional hetero ring | 69 |
20080221076 | Crystalline Sodium Salt of Cephalosporin Antibiotic - The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of crystalline Ceftiofur sodium of formula (I). | 09-11-2008 |
20090012054 | Cephem Compounds and Use as Antimicrobial Agents - The present invention provides a compound of the formula [I]: wherein R1 is lower alkyl, etc. and R2 is hydrogen, etc., or R1 and R2 are bonded together to form lower alkylene; R3 is a group represented by wherein R6 and R7 are independently optionally protected amino, etc.; m and n are independently an integer of 0 to 6; R8 and R9 are independently optionally protected amino, etc., and q and r are independently an integer of 0 to 6, or R8 and R9, together with the adjacent alkylene(s) and the nitrogen atom, form saturated nitrogen-containing heterocycle optionally having substituent(s); R4 is lower alkyl, etc.; and R5 is amino, etc., or a pharmaceutically acceptable salt thereof. | 01-08-2009 |
20090082325 | Cefidinir Oral Suspension - The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension. | 03-26-2009 |
20090176755 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBIOTIC - The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form. | 07-09-2009 |
20100009955 | PHARMACEUTICAL COMPOSITIONS OF CEFIXIME - A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients. | 01-14-2010 |
20110190253 | METHOD FOR TREATING TUBERCULOSIS - The present invention generally relates to methods for treating tuberculosis in a subject comprising administering to the subject an antibiotic in conjunction with clavulanic acid or salt thereof. The antibiotic can be carbapenem (e.g., meropenem or imipenem) or cefuroxime. The present invention also relates to related pharmaceutical compositions and methods for manufacturing said pharmaceutical compositions. | 08-04-2011 |
20110190254 | CEPHALOSPORIN HAVING CATECHOL GROUP - The present invention provides Cephem compounds which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria as follows: | 08-04-2011 |
20120115836 | STABLE LIQUID FORMULATIONS OF ANTI-INFECTIVE AGENTS AND ADJUSTED ANTI-INFECTIVE AGENT DOSING REGIMENS - Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of the infective organism. Methods of treating a cefepime resistant bacterial infection in a patient are also provided. | 05-10-2012 |
20130296290 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296291 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296292 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130296293 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-07-2013 |
20130303504 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 11-14-2013 |
20140171401 | NOVEL PHARMACEUTICAL FORMULATION OF CEFIXIME FOR ENHANCED BIOAVAILABILITY - A chewable tablet comprising Cefixime having a mean particle size between 20μ and 120μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20μ and 120μ, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets. | 06-19-2014 |
20140221331 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT - The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate programmed cell death in the microorganisms and thereby promote dispersal of microorganism from biofilms and/or inhibit biofilm formation or development. More particularly, the invention relates to the use of compounds to provide spatial and temporal control over nitric oxide release. | 08-07-2014 |
20140274999 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE - Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step. | 09-18-2014 |
20140275000 | CEFTOLOZANE PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions can include an amount of sodium chloride effective to stabilize ceftolozane in an antibiotic formulation. | 09-18-2014 |
20140323459 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 10-30-2014 |
20150031659 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 01-29-2015 |
20150031660 | 1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 01-29-2015 |
20150038478 | BETA-LACTAMASE INHIBITORS - Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains. | 02-05-2015 |
20150038479 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 02-05-2015 |
20150045338 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 02-12-2015 |
20150111864 | CRYSTALLINE FORM OF A BETA-LACTAMASE INHIBITOR - This disclosure provides compositions containing solid forms of (2S,5R)-2-(5-(3-aminopropyl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate, and methods of manufacturing and using these compositions. | 04-23-2015 |
514203000 | 3-position substituent contains pyridine ring | 23 |
20080318919 | Cefquinome Compositions and Methods of Their Use - This invention is directed generally to cefquinome compositions, processes for making such compositions, uses of such compositions to make medicaments, kits for making such compositions, and methods for using such compositions and kits to treat infections. | 12-25-2008 |
20090131394 | BROAD SPECTRUM BETA-LACTAMASE INHIBITORS - Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections. | 05-21-2009 |
20090306035 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest - Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic formulations comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided. | 12-10-2009 |
20100197650 | COMPOSITIONS AND METHODS OF TREATMENT COMPRISING CEFTAROLINE - The present invention provides compositions comprising ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infection, which include administering an effective amount of ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent. | 08-05-2010 |
20110046102 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE OF SAME AS DRUGS, ESPECIALLY BETA-LACTAMASE INHIBITORS - The invention concerns the compounds meeting formula (I: | 02-24-2011 |
20120010180 | SOLUBLE DOSAGE FORMS CONTAINING CEPHEM DERIVATIVES SUITABLE FOR PARENTERAL ADMINISTRATION - The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration. | 01-12-2012 |
20120071457 | METALLO-BETA-LACTAMASE INHIBITORS - A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics. | 03-22-2012 |
20120122832 | METHOD OF MAKING CEFQUINOME PARTICLES - Disclosed is a process for the production of particles of a cefquinome acid addition salt, preferably cefquinome sulfate particles, by precipitation of cefquinome acid addition salt, preferably the sulfate, from a cefquinome betaine solution, wherein acid, preferably sulfuric acid, is added to the betaine solution. According to the invention the acid, preferably sulfuric acid, is added quickly in a single shot, in a molar excess of 40% to less than 100%. As a result, particles are formed that comprise agglomerates of microscale primary crystalline particles. This enables providing particles of cefquinome acid addition salt, preferably cefquinome sulfate, in particle sizes commensurate with micronized material, but with improved stability. | 05-17-2012 |
20120214781 | Antibacterial Food Composition - The present invention relates to an antibacterial food composition comprising a | 08-23-2012 |
20120264727 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. | 10-18-2012 |
20130079319 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP - A compound of the formula: | 03-28-2013 |
20130172309 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF A CARBAPANEMASE GENE - Compositions and methods for the rapid and sensitive detection of a carbapenemase in a sample are provided. The compositions include novel primer and probe compositions for use in detecting the presence of this enzyme in a sample, particularly using PCR methods. These primers and probe sets can be used in amplification methods (such as PCR, particularly quantitative PCR) and packaged into kits for use in amplification methods for the purpose of detecting carbapenemase in a test sample, particularly a patient sample, particularly a direct sample. Thus, in one embodiment, the present invention provides for novel oligonucleotide primers set forth in SEQ ID NOs:1, 2, 4, 5, 7, 8, 14, 15, 17, 18, and 20, and the novel oligonucleotide probe sequences set forth in SEQ ID NOs:3, 6, 9, 16, and 19. These sequences can be used in a method of detecting carbapenemase in a sample. | 07-04-2013 |
20130178455 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. | 07-11-2013 |
20130281425 | USE OF LIQUID MEDIUM EXCHANGE BY CROSS FLOW FILTRATION IN THE PREPARATION OF DRUG SUSPENSIONS - Disclosed is a method of making particles of a drug wherein use is made of diafiltration. The diafiltration can be with anti-solvent, in which case a precipitate is obtained of particles as such. The diafiltration can also be with a pharmaceutically acceptable suspension medium. In that case several process steps of isolating, drying, transporting of particles can be avoided, because the suspension resulting from the synthesis of the particles is directly turned into a final drug product formulation. | 10-24-2013 |
20130289012 | 1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 10-31-2013 |
20140088070 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 03-27-2014 |
20140249126 | ANTIBACTERIAL COMPOUNDS - The present invention relates to cephalosporin antibacterial compounds of Formula (I): | 09-04-2014 |
20140256697 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP - A compound represented by formula (I) or a pharmaceutically acceptable salt thereof wherein A represents a group represented by one of formulae (i)-(iii); B represents a group represented by formula (v) or (vi); and E represents a substituted or unsubstituted heterocyclic group having a cationic nitrogen atom. | 09-11-2014 |
20150011524 | BROAD SPECTRUM BETA-LACTAMASE INHIBITORS - Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections. | 01-08-2015 |
20150025053 | CEPHALOSPORIN COMPOUND - The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., | 01-22-2015 |
20150141394 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 05-21-2015 |
20150344502 | CEPHEM COMPOUND - A compound of the formula: | 12-03-2015 |
20160031906 | Derivatized 3-Styryl-Cephalosporins - Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making betalactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections. | 02-04-2016 |
514204000 | 3-position substituent contains sulfur | 15 |
20140128359 | N-Heterocyclic Substituent-Containing Antibiotic, Preparation and Use Thereof - The invention relates to N-heterocyclic substituent-containing antibiotics, their preparation, and their use. Disclosed are sodium and potassium salts of 7-(α-((N,N′-diisopropylamidino)thio)acetylamino)-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-diox o-1,2,4-triazin-3-yl)thio)methyl) cephalosporanic acid as presented by the general structure (I), their preparation, and their use. The antibiotics of the invention can be used to treat diseases caused by Gram-positive or Gram-negative bacteria such as septicaemia, gastrointestinal tract infection, and urinary tract infection. They have increased half-life in blood and lowered toxicity. They can reduce the frequency of drug use and lower medical treatment costs. They have improved stability and can be stored at ambient temperatures. The method of the invention is simple, and it produces high purity products which can meet the requirements of clinical use. | 05-08-2014 |
514205000 | The additional hetero ring is part of a polycyclo ring system | 1 |
20160073634 | BETA-LACTAMASE TARGETED PHOTOSENSITIZER FOR PESTICIDE AND PEST DETECTION - Photoactivatable pesticide compounds and methods for the use thereof in the elimination and detection of pests are provided. | 03-17-2016 |
514206000 | 7-position substituent contains hetero ring | 13 |
20090075967 | DEUTERIUM-ENRICHED CEFTRIAXONE - The present application describes deuterium-enriched ceftriaxone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20110046103 | Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-Containing Compositions - The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described. | 02-24-2011 |
20110059933 | CRYSTALLINE SODIUM SALT OF CEPHALOSPORIN ANTIBIOTIC - The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I). | 03-10-2011 |
20110098266 | METHOD OF ADMINISTERING AN INJECTABLE ANTIBIOTIC TO AN ANIMAL - A method of administering an antibiotic to an animal in need thereof, including the step of injecting the antibiotic subcutaneously at the junction of a pinna with the cranium of the animal, is disclosed. | 04-28-2011 |
20110136777 | CRYSTALLINE SODIUM SALT OF CEPHALOSPORIN ANTIBIOTIC - Polymorphs of Ceftiofur sodium as a crystalline product and a process for the preparation of polymorphs of crystalline Ceftiofur sodium of formula (I). | 06-09-2011 |
20120283237 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS - The present invention provides novel cephalosporin derivatives of formula I, | 11-08-2012 |
20120322783 | TUMESCENT ANTIBIOTIC SOLUTION - Disclosed herein are solutions and kits for tumescent antibiotic delivery. Embodiments of the solution comprise an antibiotic component, an anesthetic component and a vasoconstrictor component. In addition, a method of use is disclosed comprising subcutaneous delivery of the solution. The disclosed solution, kit and method of subcutaneous delivery can be used for a variety of surgical procedures including liposuction, mastectomy and others. The tumescent antibiotic solution can be administered to a patient in situations where establishing IV access is difficult, impossible, or undesirable. A variety of delivery methods appropriate for surgical settings, as well as for use by first responders are likewise disclosed. | 12-20-2012 |
20120329770 | CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to cephalosporin derivatives having β-lactamase inhibitory activity. The compounds are useful in preventing or treating bacterial resistance to an antibiotic, e.g. a β-lactam antibiotic. Disclosed herein are compounds that are inhibitors of class B metallo-β-lactamases, as well as class A, C, and D serine β-lactamases. In some preferred embodiments, the compounds are 3′-thiobenzoate derivatives of a cephalosporin. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the compounds are also disclosed. | 12-27-2012 |
20130137670 | ZWITTERION SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY - A formulation is provided that includes a volume of an aqueous multivalent physiological ion solution compatible with cerebrospinal fluid containing at least one divalent cation of magnesium or calcium, and at least one anion of carbonate or phosphate, and having a pH between 6.5 and 8.0. A zwitterionic therapeutic agent other than baclofen is dissolved the solution to achieve higher concentration or ease of solution and/or storage relative to therapeutic saline solutions of the same agent. A process of delivering a zwitterionic therapeutic agent into a subject is provided that includes dissolving a therapeutic amount of the zwitterionic therapeutic agent in a volume of artificial cerebrospinal fluid to form a stable formulation. The solution is then administered to the subject using an intrathecal pump. | 05-30-2013 |
20130143857 | PHARMACEUTICAL COMPOSITIONS OF CEFDITOREN PIVOXIL - The present invention relates to a pharmaceutical composition comprising Cefditoren pivoxil, water soluble high molecular weight substance and one or more pharmaceutically acceptable excipient wherein weight ratio of high molecular weight substance to Cefditoren pivoxil is greater than 1:4 and a process for preparation thereof. | 06-06-2013 |
20130296294 | TREATMENT AND/OR PREVENTION OF PARKINSON'S DISEASE DEMENTIA WITH CEFTRIAXONE - Disclosed herein is a method for treatment of a human subject having or suspected of having Parkinson's disease dementia, which includes administering to the human subject ceftriaxone at a daily dosage ranging from about 1.5 mg to about 35 mg per kilogram of a body weight of the human subject. | 11-07-2013 |
20150290210 | COMPOSITION AND METHODS OF TREATMENT OF BACTERIAL MENINGITIS - A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure. | 10-15-2015 |
20160082016 | Use of Clonazepam in Combination with Antibiotic in the Treatment of Bacterially Induced Meningitis - The present invention relates to the use of a well-known benzodiazepine compound, namely clonazepam, in combination with antibiotic agents, for treating bacterially induced meningitis. | 03-24-2016 |
514207000 | Alkyl, hydroxyalkyl, alkoxyalkyl or alkanoyloxyakyl bonded directly to 3-position | 7 |
20090197855 | PHARMACEUTICAL COMPOSITIONS OF CEFDINIR - A chewable tablet dosage form comprising Cefdinir or pharmaceutically acceptable salts thereof for the oral administration of Cefdinir in a manner that is more palatable and less objectionable to population group's especially young children and older patients. A method of preparing the chewable tablets comprising Cefdinir and method of treatment using the same. | 08-06-2009 |
20110301139 | PHARMACEUTICAL COMPOSITIONS OF CEFIXIME - A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients. | 12-08-2011 |
20130203726 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS - The present invention relates to the use of inhibitors of FtsZ, an ancestral tubulin of prokaryotes, to restore susceptibility to β-lactam antibiotics, including carbapenems and cephalosporins, particularly in methicillin-resistant | 08-08-2013 |
20130345190 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 12-26-2013 |
20140275001 | CRYSTALLINE FORM OF A BETA-LACTAMASE INHIBITOR - This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions. | 09-18-2014 |
20150299223 | 2-SUBSTITUTED CEPHEM COMPOUNDS - The present invention relates to 2-substituted cephem compounds of Formula (I) having a quaternary ammonium group on the 3-side chain, preferably together with a cathechol group, or pharmaceutically acceptable salts thereof, which exhibit potent antimicrobial spectrum against a variety of bacteria including Gram negative bacteria and/or Gram positive bacteria, corresponding pharmaceutical compositions, methods of making, treatment methods for bacterial infections or uses thereof. | 10-22-2015 |
20170233408 | SALT FORMS OF CEFTOLOZANE | 08-17-2017 |
514209000 | Alkyl, hydroxyalkyl, alkoxyalkyl, or alkanoyloxyakyl bonded directly to 3-position | 3 |
20090306036 | METHODS OF SCREENING AGENTS, CONJUGATES OR CONJUGATE MOIETIES FOR TRANSPORT BY A PEPT2 TRANSPORTER - The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter. | 12-10-2009 |
20110112059 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS AND THERAPEUTIC AND DIAGNOSTIC METHODS OF USING SAME - The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases. | 05-12-2011 |
20130217659 | PROCESS FOR THE CRYSTALLISATION OF CEFADROXIL MONOHYDRATE - Cefodroxil monohydrate is formed by a processing which includes a) bringing an aqueous solution of cefadroxil monohydrate to a pH of between 7 to 9 with a suitable titrant; b) lowering the pH to a value of between 5 and 6.5 to obtain a suspension of cefadroxil monohydrate in crystal form; and c) isolating the cefadroxil monohydrate in crystal form from the suspension obtained in step b). The cefadroxil monohydrate thereby obtained exhibits a CIE b value of below 6, and advantageously a CIE b value of below 12 when stored at a temperature of 25° C. for at least 1 month. | 08-22-2013 |